Abstract A01: Exploring phosphatase and tensin homolog (PTEN) loss as a potential predictive marker for response to everolimus in patients with pancreatic neuroendocrine tumors (PNETs)
Conclusion: The index case for this study had a PTEN deletion and had a partial response to treatment and prolonged disease control for 2 years with everolimus. Testing is ongoing in additional cases to determine if there is a consistent correlation between PTEN loss by FISH and PFS.Citation Format: Moh'd Khushman, Joyce Slingerland, Yao-Shan Fan, Monica Garcia-Buitrago, Ernesto Bustinza, Maria Restrepo, Daniel Sussman, Caio Rocha-Lima, Peter Hosein. Exploring phosphatase and tensin homolog (PTEN) loss as a potential predictive marker for response to everolimus in patients with pancreatic neuroendocrine tumors (PNETs). [abstract]. In: Proceedings of the AACR Special Conference: Targeting the PI3K-mTOR Network in Cancer; Sep 14-17, 2014; Philadelphia, PA. Philadelphia (PA): AACR; Mol Cancer Ther 2015;14(7 Suppl):Abstract nr A01.
Source: Molecular Cancer Therapeutics - Category: Cancer & Oncology Authors: Khushman, M., Slingerland, J., Fan, Y.-S., Garcia-Buitrago, M., Bustinza, E., Restrepo, M., Sussman, D., Rocha-Lima, C., Hosein, P. Tags: Clinical Data with PI3K and mTOR Inhibitors: Poster Presentations - Proffered Abstracts Source Type: research
More News: Cancer | Cancer & Oncology | Conferences | Gastroenterology | Genetics | Liver | Neurology | Pancreas | Pancreatic Cancer | Pathology | Sandostatin | Study | Urology & Nephrology